Giulia Maria Ferrari
Research Subjects
Giulia Maria Ferrari has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Adriana Balduzzi
Pediatric Hematology Department, Fondazione MBBM, University of Milano Bicocca, Monza, Italy
1 shared publicationAndrea Biondi
Pediatric Hematology Department, Fondazione MBBM, University of Milano Bicocca, Monza, Italy
1 shared publication- Anna Paola Marcello
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy
1 shared publication - Anna Zaninoni
SC Ematologia, SS Fisiopatologia delle Anemie, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, Italy
1 shared publication Antonella Colombini
Pediatric Hematology-Oncology Unit Department of Pediatrics, University of Milan-Bicocca , Monza, Italy
1 shared publication- Bruno Fattizzo
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 10 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7722
Not-So-Rare Defects of RBC Lipidic Composition: Four New Cases of Flippase Deficiency Due to ATP11C Mutations
Adenosine Triphosphatase (ATPase) Phospholipid Transporting 11C gene (ATP11C), located on the X chromosome, encodes the major phosphatidylserine flippase in human erythroid cells. Only five patients have so far been reported with defective ATP11C, displaying mild hemolytic anemia and reduced flippase activity. In this study, we report four Italian male patients in three unrelated families with novel private mutations in the ATP11C gene, resulting in impaired flippase activity associated with mild/compensated hemolytic anemia. The decreased flippase activity was measured as % of phosphatidylserine internalization over time and ranged after 20 min incubation from 5% to 18.6% in all patients, regardless of the type of molecular defect. Flippase activity was also tested in healthy controls, ranging from 43% to 62% in both males and females. This measurement appears to be a useful tool for hypothesizing ATP11C abnormalities in male subjects with mild compensated hemolysis, prior to next generation sequencing (NGS) analysis. Although rare, ATP11C mutations may be underrecognized, and therefore should be suspected and investigated in male patients presenting with subtle hemolytic signs or symptoms.
- 10 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7722
Open AccessNot-So-Rare Defects of RBC Lipidic Composition: Four New Cases of Flippase Deficiency Due to ATP11C Mutations
Adenosine Triphosphatase (ATPase) Phospholipid Transporting 11C gene (ATP11C), located on the X chromosome, encodes the major phosphatidylserine flippase in human erythroid cells. Only five patients have so far been reported with defective ATP11C, displaying mild hemolytic anemia and reduced flippase activity. In this study, we report four Italian male patients in three unrelated families with novel private mutations in the ATP11C gene, resulting in impaired flippase activity associated with mild/compensated hemolytic anemia. The decreased flippase activity was measured as % of phosphatidylserine internalization over time and ranged after 20 min incubation from 5% to 18.6% in all patients, regardless of the type of molecular defect. Flippase activity was also tested in healthy controls, ranging from 43% to 62% in both males and females. This measurement appears to be a useful tool for hypothesizing ATP11C abnormalities in male subjects with mild compensated hemolysis, prior to next generation sequencing (NGS) analysis. Although rare, ATP11C mutations may be underrecognized, and therefore should be suspected and investigated in male patients presenting with subtle hemolytic signs or symptoms.
- Open Access
- 7 November 2022
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 1031687
Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this condition prior to adulthood. Though pediatric patients rarely present the typical features and outcomes usually observed in older people, pediatric myelofibrosis is not considered an independent entity. Here we aim to describe patients with pediatric myelofibrosis, showing different clinical and pathological features when compared to the World Health Organization 2016 Primary Myelofibrosis classification. We retrospectively collected and analyzed 14 consecutive pediatric myelofibrosis diagnosed in our Pediatric hematology outpatient clinic over a six-year period. According to clinical data and bone marrow biopsy findings, patients were classified into three subgroups: adult-like myelofibrosis, pediatric immune myelofibrosis, idiopathic myelofibrosis. Pediatric Immune Myelofibrosis was the predominant subgroup in our cohort (7/14). Pediatric Immune Myelofibrosis is characterized by peculiar bone marrow features (i.e., T lymphocyte infiltration) and a milder course compared to the other patients Pediatric Immune Myelofibrosis is a novel and distinct pathological entity. We suggest to carefully consider Pediatric Immune Myelofibrosis in case of bone marrow biopsies showing myelofibrosis that do not fulfill WHO criteria.
- 7 November 2022
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 1031687
Open AccessPediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this condition prior to adulthood. Though pediatric patients rarely present the typical features and outcomes usually observed in older people, pediatric myelofibrosis is not considered an independent entity. Here we aim to describe patients with pediatric myelofibrosis, showing different clinical and pathological features when compared to the World Health Organization 2016 Primary Myelofibrosis classification. We retrospectively collected and analyzed 14 consecutive pediatric myelofibrosis diagnosed in our Pediatric hematology outpatient clinic over a six-year period. According to clinical data and bone marrow biopsy findings, patients were classified into three subgroups: adult-like myelofibrosis, pediatric immune myelofibrosis, idiopathic myelofibrosis. Pediatric Immune Myelofibrosis was the predominant subgroup in our cohort (7/14). Pediatric Immune Myelofibrosis is characterized by peculiar bone marrow features (i.e., T lymphocyte infiltration) and a milder course compared to the other patients Pediatric Immune Myelofibrosis is a novel and distinct pathological entity. We suggest to carefully consider Pediatric Immune Myelofibrosis in case of bone marrow biopsies showing myelofibrosis that do not fulfill WHO criteria.
- Open Access
- 1 August 2014
- Published by MDPI AG in Hematology Reports
- Vol. 6 (3) , 5554
Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment
In the last two decades great improvements have been made in the treatment of childhood acute lymphoblastic leukemia, with 5-year overall survival rates currently approaching almost 90%. In comparison, results reported in adolescents and young adults (AYAs) are relatively poor. In adults, results have improved, but are still lagging behind those obtained in children. Possible reasons for this different pattern of results include an increased incidence of unfavorable and a decreased incidence of favorable cytogenetic abnormalities in AYAs compared with children. Furthermore, in AYAs less intensive treatments (especially lower cumulative doses of drugs such as asparaginase, corticosteroids and methotrexate) and longer gaps between courses of chemotherapy are planned compared to those in children. However, although favorable results obtained in AYAs receiving pediatric protocols have been consistently reported in several international collaborative trials, physicians must also be aware of the specific toxicity pattern associated with increased success in AYAs, since an excess of toxicity may compromise overall treatment schedule intensity. Cooperative efforts between pediatric and adult hematologists in designing specific protocols for AYAs are warranted.
- 1 August 2014
- Published by MDPI AG in Hematology Reports
- Vol. 6 (3) , 5554
Open AccessRationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment
In the last two decades great improvements have been made in the treatment of childhood acute lymphoblastic leukemia, with 5-year overall survival rates currently approaching almost 90%. In comparison, results reported in adolescents and young adults (AYAs) are relatively poor. In adults, results have improved, but are still lagging behind those obtained in children. Possible reasons for this different pattern of results include an increased incidence of unfavorable and a decreased incidence of favorable cytogenetic abnormalities in AYAs compared with children. Furthermore, in AYAs less intensive treatments (especially lower cumulative doses of drugs such as asparaginase, corticosteroids and methotrexate) and longer gaps between courses of chemotherapy are planned compared to those in children. However, although favorable results obtained in AYAs receiving pediatric protocols have been consistently reported in several international collaborative trials, physicians must also be aware of the specific toxicity pattern associated with increased success in AYAs, since an excess of toxicity may compromise overall treatment schedule intensity. Cooperative efforts between pediatric and adult hematologists in designing specific protocols for AYAs are warranted.